Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lin Shen

Showing results (1421-1430 of 1,553) with videos related to

Pageof 156
Sort By:
Journal of Translational Medicine|January 13, 2025
A humanized anti-MSLN×4-1BB bispecific antibody exhibits potent antitumour activity through 4-1BB signaling activation and fc function without systemic toxicityDa-Yan Zhang, Zhi-Hua Zhang, Wen-Ting Liu, et al.
Nature|December 16, 2021
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancerYelena Y Janjigian, Akihito Kawazoe, Patricio Yañez, et al.
Eclinicalmedicine|April 28, 2022
Update and validation of a diagnostic model to identify prevalent malignant lesions in esophagus in general populationMengfei Liu, Ren Zhou, Zhen Liu, et al.
Cell Reports. Medicine|January 9, 2024
Multi-omics of the gut microbial ecosystem in patients with microsatellite-instability-high gastrointestinal cancer resistant to immunotherapySiyuan Cheng, Zihan Han, Die Dai, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2022
Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)Jiarui Li, Yuejuan Cheng, Chunmei Bai, et al.
Journal of Hematology & Oncology|May 8, 2026
Chinese guidelines for HER2-targeted therapy in gastric and gastroesophageal junction adenocarcinoma (2025 Edition)Xiaotian Zhang, Yakun Wang, Muyan Cai, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|January 10, 2026
Anacardic acid mitigates post‑MI cardiac fibrosis via suppressing p38/JNK-GATA3 pathway and H3K9ac‑dependent epigenetic regulationWenjing Huang, Xuemei Wang, Xin Yan, et al.
Signal Transduction and Targeted Therapy|March 20, 2025
Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II studyDan Liu, Jifang Gong, Jian Li, et al.
BMC Cancer|August 6, 2017
Clinicopathological features and prognostic validity of WHO grading classification of SI-NENsLuohai Chen, Lin Zhou, Meng Zhang, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 4, 2021
Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumorsYingying Xu, Yakun Wang, Jifang Gong, et al.
Pageof 156

Showing results (1421-1430 of 1,553) with videos related to

Sort By:
Pageof 156
Journal of Translational Medicine|January 13, 2025
A humanized anti-MSLN×4-1BB bispecific antibody exhibits potent antitumour activity through 4-1BB signaling activation and fc function without systemic toxicityDa-Yan Zhang, Zhi-Hua Zhang, Wen-Ting Liu, et al.
Nature|December 16, 2021
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancerYelena Y Janjigian, Akihito Kawazoe, Patricio Yañez, et al.
Eclinicalmedicine|April 28, 2022
Update and validation of a diagnostic model to identify prevalent malignant lesions in esophagus in general populationMengfei Liu, Ren Zhou, Zhen Liu, et al.
Cell Reports. Medicine|January 9, 2024
Multi-omics of the gut microbial ecosystem in patients with microsatellite-instability-high gastrointestinal cancer resistant to immunotherapySiyuan Cheng, Zihan Han, Die Dai, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2022
Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)Jiarui Li, Yuejuan Cheng, Chunmei Bai, et al.
Journal of Hematology & Oncology|May 8, 2026
Chinese guidelines for HER2-targeted therapy in gastric and gastroesophageal junction adenocarcinoma (2025 Edition)Xiaotian Zhang, Yakun Wang, Muyan Cai, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|January 10, 2026
Anacardic acid mitigates post‑MI cardiac fibrosis via suppressing p38/JNK-GATA3 pathway and H3K9ac‑dependent epigenetic regulationWenjing Huang, Xuemei Wang, Xin Yan, et al.
Signal Transduction and Targeted Therapy|March 20, 2025
Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II studyDan Liu, Jifang Gong, Jian Li, et al.
BMC Cancer|August 6, 2017
Clinicopathological features and prognostic validity of WHO grading classification of SI-NENsLuohai Chen, Lin Zhou, Meng Zhang, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 4, 2021
Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumorsYingying Xu, Yakun Wang, Jifang Gong, et al.
Pageof 156